• Luminal Gastroenterology
• 31 min
  1. Novel treatments for GI malignancies

  • Prof. Bert H. O'Neil
• 40 min
  2. The spectrum of GERD implications for assessment and management

  • Prof. Eamonn M. M. Quigley
• 54 min
  3. Oro-pharyngeal and esophageal motility and dysmotility

  • Dr. John E. Pandolfino
• 55 min
  4. Eosinophilic esophagitis and other non-reflux esophageal disorders

  • Prof. David Katzka
• 39 min
  5. Disorders of gastric function: gastroparesis and functional dyspepsia 1

  • Dr. Braden Kuo
• 17 min
  6. Disorders of gastric function: gastroparesis and functional dyspepsia 2

  • Dr. Braden Kuo
• 48 min
  7. Acid-peptic diseases of the stomach and duodenum including Helicobacter pylori and NSAIDs

  • Prof. Sheila Crowe
• 48 min
  8. Gastric cancer, gastritis and the role of H. pylori

  • Prof. Anthony Axon
• 48 min
  9. Celiac disease

  • Prof. Ciaran Kelly
• 43 min
  10. IBD for the non-gastroenterologist

  • Prof. Sunanda Kane
• 34 min
  11. The enteric microbiota in health and disease

  • Dr. Francisco Guarner
• 45 min
  12. Colorectal cancer and hereditary colon cancer syndromes

  • Prof. Carol A. Burke
• 39 min
  13. The spectrum of GI ischemia 1

  • Prof. Lawrence J. Brandt
• 31 min
  14. The spectrum of Gl ischemia 2

  • Prof. Lawrence J. Brandt
• 41 min
  15. Constipation and defecation disorders

  • Prof. Satish S. C. Rao
• 40 min
  16. Diverticular disease of the colon

  • Dr. Dale Vimalachandran
• 73 min
  17. Irritable bowel syndrome (IBS)

  • Prof. Eamonn M. M. Quigley
• 27 min
  18. Evidence-based management of non-variceal upper GI bleeding

  • Prof. Joseph J. Sung
• Hepatology
• 32 min
  19. Hepatitis B virus (HBV)

  • Prof. Marco Olivera-Martinez
• 26 min
  20. Hepatitis C - cure of infection

  • Prof. Mark Mailliard
• 46 min
  21. Drug-induced liver injury: importance, epidemiology, and mechanisms of DILI

  • Prof. James H. Lewis
• 26 min
  22. Drug-induced liver injury: risk factors and drug development in DILI

  • Prof. James H. Lewis
• 39 min
  23. Drug-induced liver injury: HDS, diagnosing, treating and preventing DILI

  • Prof. James H. Lewis
• 22 min
  24. Portal hypertension

  • Prof. John Reinus
• 55 min
  25. Portal hypertension: at the bedside

  • Dr. Clara Y. Tow
• 29 min
  26. The management of chronic liver disease, including transplantation 1

  • Prof. Timothy M. McCashland
• 21 min
  27. The management of chronic liver disease, including transplantation 2

  • Prof. Timothy M. McCashland
• 34 min
  28. Hereditary hemochromatosis: what have we learnt from population studies

  • Prof. John K. Olynyk
• 38 min
  29. Immune-mediated liver disease

  • Dr. Jenny Heathcote
• 51 min
  30. Alcoholic liver disease

  • Prof. Michael Lucey
• The Pancreas and Biliary Tree
• 46 min
  31. Acute pancreatitis

  • Prof. Davor Štimac
• 49 min
  32. Chronic pancreatitis

  • Prof. Christopher Forsmark
• 47 min
  33. Pancreatic cancer

  • Prof. Randall Brand
• 20 min
  34. The management of gallstones in relation to laparoscopic cholecystectomy and gallbladder dyskinesia

  • Prof. John Baillie
• Archived Lectures *These may not cover the latest advances in the field
• 52 min
  35. The management of other aspects of chronic liver disease, including transplantation

  • Prof. Timothy M. McCashland
• 38 min
  36. Chronic viral hepatitis B and C

  • Prof. Mark Mailliard
• 41 min
  37. Pancreatic cancer

  • Prof. Randall Brand
• 72 min
  38. Acute viral hepatitis

  • Prof. Geoffrey Dusheiko
• 33 min
  39. Diverticular disease

  • Dr. Charles Knowles
• 57 min
  40. The spectrum of gastrointestinal ischemia: 2010

  • Prof. Lawrence J. Brandt
• 51 min
  41. Acute pancreatitis

  • Prof. Davor Štimac

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Objectives: Chronic Viral Hepatitis B & C
3. The Human Hepatitis Viruses
4. Chronic HBV: A Global Health Problem
5. Immigration & Global HBV: "An Asian Disease"
6. HBV Transmission
7. Markers of HBV Infection
8. Natural History of HBV Infection
9. Natural History of Chronic HBV (1)
10. Natural History of Chronic HBV (2)
11. Phases of Chronic HBV Infection
12. Goals of Antiviral Treatment
13. Who Should Be Treated?
14. Guidelines of Chronic HBV Treatment (AASLD)
15. HBV Genotype Impact on Disease Progression
16. Response to Antiviral Therapy for HBV
17. Initial Treatment Considerations
18. PegINF vs. Nucleos(t)ide Analogs
19. Virologic Response in HBeAg+ Chronic HBV
20. Response to Therapy in HBeAg+ Chronic HBV
21. Virologic Response in HBeAg- Chronic HBV
22. Response to Therapy in HBeAg- Chronic HBV
23. Antiviral Drug Resistance in HBV
24. Antiviral Treatment Failure in HBV
25. Strategies to Limit Resistance
26. Monitor Response to HBV Therapy
27. Screen for HBsAg
28. HBV Vaccination
29. Chronic Hepatitis C: A Global Health Problem
30. At Risk for HCV
31. Global Risk from Nosocomial HCV
32. Hepatitis C - Natural History
33. Progression of Fibrosis in HCV Infection
34. Markers of HCV Infection
35. Goals of HCV Therapy
36. Interferons
37. Ribavirins
38. SVR by HCV Genotype in Naive Patients
39. Factors Predicting a Sustained Viral Response
40. Antiviral Therapy of HCV- Special Populations
41. Complications in Combination Therapy for HCV
42. HCV RNA: Sites for Drug Inhibition
43. Chronic HCV Therapy Strategy
44. HCV Protease Inhibition NS3-4A Complex
45. Telaprevir + PegIFN-2a and RBV
46. HCV Therapy Near New Horizons
47. Summary: Chronic Hepatitis B & C

Topics Covered

• Diagnosis, Natural History and Therapy of Hepatitis B
• Diagnosis, Natural History and Therapy of Hepatitis C

Links

Series:

• Gastroenterology and Hepatology

Categories:

• Clinical Practice

Therapeutic Areas:

• Gastroenterology & Nephrology

Talk Citation

Publication History

• Published on January 5, 2011
• Archived on July 22, 2016

Financial Disclosures

• Prof. Mark Mailliard, Grant/Research Support (Principal Investigator): Gilead Sciences